All In Biotech

Drug Trial Radar · NCT06394713

A Study to Evaluate the Efficacy and Safety of QLF31907 Combination Therapy in Patients With Advanced Malignant Tumors

A Phase 1b/2 Trial to Evaluate the Efficacy and Safety of QLF31907 (PD-L1/4-1BB Bi-specific Antibody) Combination Therapy in Patients With Advanced Malignant Tumors

Last checked: Nov 19, 2026Latest source record: May 1, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Jun 15, 2024

Primary completion

Jun 15, 2025

Study completion Dec 15, 2026

Sponsor

Lead sponsor
Qilu Pharmaceutical Co., Ltd.Industry
Sponsor type
Industry
First posted
May 1, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed to evaluate the safety and efficacy of QLF31907 combination therapy in advanced malignant tumors.

Conditions

  • Advanced Malignant Neoplasm

Interventions

  • QLF31907Drug

    intravenous administration, once every 3 weeks

  • IrinotecanDrug

    intravenous administration, 125 mg/m2, d1 and d8, every 3 weeks

  • DocetaxelDrug

    intravenous administration, 75mg/m2, d1, every 3 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. phase Ib: Dose-limiting toxicity(DLT)Time frame: 28 days
  2. phase2: objective response rate(ORR)Time frame: up to 2 years

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.